Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2008
Business Overview: Novavax is a clinical-stage biotechnology company focused on developing novel vaccines using proprietary virus-like-particle (VLP) technology. Key targets include H5N1 pandemic influenza, seasonal influenza, and Varicella Zoster. The company is transitioning away from its previous drug delivery platform (MNP technology) and the commercialization of Estrasorb, having sold related assets to Graceway Pharmaceuticals in February 2008.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2008 |
Six Months Ended June 30, 2007 |
|---|---|---|---|
| Total Revenues | $342 | $800 | $245 |
| Net Loss | $(9,372) | $(17,127) | $(16,582) |
| Net Loss Per Share (Basic/Diluted) | $(0.15) | $(0.28) | $(0.27) |
| Research & Development Expenses | $5,380 | $9,814 | $7,645 |
| Cash and Cash Equivalents (Balance) | $23,513 (as of June 30, 2008) | ||
| Short-term Investments | $12,372 (as of June 30, 2008) | ||
| Convertible Notes Outstanding | $22,000 (Principal) | ||
| Accumulated Deficit | $(216,854) (as of June 30, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues for the six months ended June 30, 2008, increased to $800,000 from $245,000 in the prior year period. This increase was driven primarily by a $474,000 rise in contract research and development revenue (largely from NIH grants), offset by the discontinuation of Gynodiol product sales.
- Operating Expenses: Research and development expenses increased by 28% ($2.2 million) year-over-year for the six-month period, reflecting expanded preclinical testing and process development for influenza vaccine candidates. General and administrative expenses decreased by 19% ($1.5 million) due to reduced facility costs and lower reserves for notes receivable from former directors.
- Discontinued Operations: The company reported a loss from discontinued operations of $1.7 million for the six months ended June 30, 2008, compared to $2.2 million in the prior year. This segment relates to the wind-down of the Philadelphia manufacturing facility and the sale of Estrasorb assets.
- Interest Income: Net interest income decreased significantly to $7,000 for the six months ended June 30, 2008, from $1.1 million in the prior year, due to lower average cash and investment balances.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: As of June 30, 2008, the company held approximately $35.9 million in cash, cash equivalents, and short-term investments. Management believes these resources, combined with a registered direct offering completed in July 2008 raising approximately $17.6 million, are sufficient to fund operations through September 2009.
- Clinical Outlook: The company is conducting Phase I/IIa clinical trials for its H5N1 pandemic influenza vaccine. Initial immunogenicity and safety data are anticipated in the third quarter of 2008, with study completion expected by the end of 2008.
- Divestiture of Estrasorb: The company completed the sale of Estrasorb assets to Graceway Pharmaceuticals. Final delivery of additional units was completed in July 2008, and the Philadelphia facility is expected to close by mid-August 2008.
- Risk Factors:
- Profitability: The company has a history of losses with an accumulated deficit of $217 million. There is no assurance it will achieve profitability.
- Auction Rate Securities: The company holds $8.9 million in auction rate securities. While management does not anticipate impairment, failed auctions could impact liquidity if the market does not recover.
- Related Party Loans: The company has outstanding notes to two former directors secured by pledged shares. If the stock price does not reach target levels, the company may not recover the full amount owed.
- Regulatory Approval: Future success depends on obtaining FDA and foreign regulatory approvals for vaccine candidates, which is uncertain.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $17.6 million raised in July 2008 combined with existing cash to sustain operations through the projected September 2009 date, given high R&D burn rates.
- Clinical Trial Results: Monitor the release of Phase I/IIa H5N1 vaccine data expected in Q3 2008, as negative results could materially impact stock price and future funding.
- Auction Rate Securities: Assess the liquidity risk associated with the $8.9 million holding in auction rate securities and the potential for impairment charges if the market remains frozen.
- Convertible Notes: Review the terms of the $22 million convertible notes (due July 2009) and the conditions triggering mandatory conversion (stock price > $7.00).
- Related Party Receivables: Evaluate the recoverability of the approximately $2 million in notes receivable from former directors, which are secured by pledged shares subject to market price targets.